Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference product Clear all
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen

NCT02097173
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate
Drug
Lead sponsor
medac GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users

NCT06691386
View directory record Official record
Conditions
Tobacco Use
Interventions
Test Product A, Test Product B, Test Product C, Test Product D, Test Product E, Reference Product F: Subjects' OBMST
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Bentonville, Arkansas • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

NCT06673641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 30, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional

Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis

NCT07595367
View directory record Official record
Conditions
Allergic Reaction (IgA) Vasculitis
Interventions
BBD-1 Multi target Immune Enhancement Targeting Agent
Drug
Lead sponsor
Qifeng Zhang
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

NCT00701636
View directory record Official record
Conditions
Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions
daptomycin
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
19 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Not applicable Interventional Results available

Resolute Integrity US Extended Length Sub-Study(RI US XL)

NCT01913600
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 30, 2026, 7:15 PM EDT
Recruiting Phase 4 Interventional

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

NCT06201676
View directory record Official record
Conditions
Orthopaedic Trauma, Chronic Opioid Use
Interventions
Ketorolac Injection, Standard of Care (SOC) Multimodal Analgesia
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

NCT02260817
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
11C-choline Injection
Drug
Lead sponsor
Global Isotopes, LLC d/b/a Zevacor Molecular
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 7:15 PM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Results available

Biological Signatures, Probiotic Among Those With mTBI and PTSD

NCT02723344
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post Traumatic Stress Disorder
Interventions
of Lactobacillus reuteri (L. reuteri; DSM 17938), Sunflower and medium chain triglyceride oils
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 2 Interventional

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

NCT05077332
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
Interventions
Famotidine, Celecoxib, Placebo
Drug · Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infant Nutrition and Brain Development

NCT03111927
View directory record Official record
Conditions
Healthy, Infant Development
Interventions
Infant Formula: enriched level of myelin-relevant nutrients, Infant formula: standard level of myelin-relevant nutrients
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
2 Weeks to 6 Weeks
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
View directory record Official record
Conditions
Hypogonadism
Interventions
Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex
Combination Product · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 3 Interventional

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

NCT02624505
View directory record Official record
Conditions
Bronchial Asthma
Interventions
90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

High-fat Meal Challenge in Pediatrics

NCT05230433
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance
Interventions
High-fat Challenge
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 30, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

Efficacy of EXPAREL vs. Bupivacaine

NCT07212114
View directory record Official record
Conditions
Total Ankle Arthroplasty, Postsurgical Analgesia
Interventions
EXPAREL, 0.25% bupivacaine (HCl): 50 ml, 0.25% bupivacaine (HCl): 30 ml
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions

NCT00939705
View directory record Official record
Conditions
Healthy
Interventions
topiramate
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 10, 2011 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque

NCT04921371
View directory record Official record
Conditions
Gingivitis, Plaque
Interventions
Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush, 5% Hydroalcohol Mouthrinse, Mouthrinse Prototype 1, Mouthrinse Prototype 2
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

NCT01260948
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 30, 2026, 7:15 PM EDT